Bluejay Diagnostics Overview
Latest ROE for Bluejay Diagnostics: -77.23% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-77.23%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bluejay Diagnostics (BJDX) currently reports a ROE of -77.23%. That is below the sector sector average of -5.72%. Use the charts on this page to explore Bluejay Diagnostics's ROE history and peer comparisons.
Bluejay Diagnostics's ROE of -77.23% is lower than the its sector sector average of -5.72%. That is roughly 1249.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Bluejay Diagnostics's current -77.23% should be judged against industry norms (sector average: -5.72%) and against BJDX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -77.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.72%. From there, open related valuation or income-statement pages for Bluejay Diagnostics, and consider following BJDX for alerts when major investors trade the stock.
